Back Bay Life Science Advisors

What Back Bay Life Science Advisors does

Back Bay Life Science Advisors is a Boston-based boutique strategy consulting and investment banking firm focused exclusively on the life sciences sector. Founded in 2010 by CEO Jonathan P. Gertler, MD, the firm operates with 11-50 employees from offices in Boston and Toronto (opened in November 2021), with FINRA/SIPC registration handled through a subsidiary that enables capital markets execution. Service lines span strategy consulting, M&A advisory, licensing advisory, and capital markets work for biotech, pharma, and medtech clients.

The firm's core assets are its senior team and institutional partnerships rather than proprietary technology. Peter Bak, PhD, was promoted to Partner and Managing Director, reinforcing a bench that combines clinical (MD) and scientific (PhD) credentials with transaction expertise. Back Bay has built a recurring content and convening franchise through its NAHC conference series (a 10th annual edition is referenced) and topical analyst coverage spanning areas such as obesity therapeutics and radiopharma, which double as thought leadership and deal origination.

Revenue mechanics are driven by advisory retainers, deal-based success fees (M&A and licensing), and capital markets transaction fees. The DNB Carnegie partnership — established alongside DNB's SEK 12 billion acquisition of Carnegie — creates a distribution corridor for US-Nordic and broader European cross-border mandates, and the firm has executed visible debt capital markets work including a EUR 180 million bond advisory for KD Pharma. Customer base is distributed across biotech, pharma, and medtech subsegments, and the private firm reported a modest $1,551,796 funding round on 2020-11-03.

Name

Back Bay Life Science Advisors

Legal name

Back Bay Life Science Advisors

Website

https://bblsa.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Back Bay Life Science Advisors is a Boston-based boutique consulting and investment banking firm serving biotech, pharma, and medtech clients with strategy, M&A, licensing, and capital markets advisory, supported by a Toronto office and a DNB Carnegie partnership.

Ownership category

akta.pro rank

Product category

Life Sciences Investment Banking

NAICS

Management, Scientific, and Technical Consulting Services (5416), Other Scientific and Technical Consulting Services (54169), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)

SIC

Services-Engineering, Accounting, Research, Management (8700), Services-Management Consulting Services (8742), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Industry-Specialist / Sector-Focused M&A Advisory (FSAEAGAJ)

akta.pro secondary industries

M&A Advisory (Buy-side/Sell-side) (BPAHADAC), Corporate Finance Advisory (Strategic Finance, Capital Structure & Recaps) (FSAEAGAE), Corporate Finance & Capital Advisory (BPAHADAB)

Keywords

• Strategy consulting services
• Investment banking advisory
• Life sciences consulting
• Biotech transaction advisory
• Healthcare equity research

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Strategic Advisory Consulting: Provides strategic guidance to life sciences companies across commercial, R&D, corporate business development and investment banking opportunities. Fees likely earned through advisory retainers, project fees, and success fees.
2. Investment Banking / Securities Services: Securities-related services provided through Back Bay Life Science Advisory LLC, a wholly-owned broker-dealer subsidiary (Member FINRA/SIPC). Covers M&A advisory, capital markets, buy-side/sell-side transactions.
3. Healthcare Equity Research: Publishes industry reports on healthcare sector authored by Back Bay experts and DNB senior equity analysts. Distributed via subscription and email.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Back Bay Life Science Advisors provides integrated strategy consulting and investment banking services to the global life sciences industry. Its core offerings include Investment Banking (M&A advisory, licensing, capital raising through its FINRA/SIPC broker-dealer subsidiary), Strategic Advisory (data-driven consulting across commercial, R&D, and corporate development), and Analytics (sector research and equity analysis), delivered to biotech, pharmaceutical, medical device companies, and investors.

Product overview

Back Bay Life Science Advisors is a consulting and investment banking firm that integrates strategic consulting with investment banking capabilities to provide comprehensive guidance to global life sciences companies. The core offerings include Investment Banking (M&A, licensing, capital raising), Strategic Advisory, and Analytics services, delivered through the DNB Carnegie Back Bay Healthcare Partnership. The company also publishes research through Healthcare Equity Analyst Reports, White Papers, and The Life Science Report podcast, covering topics across oncology, biopharma, gene therapy, and cell technology. Market Insights & Events includes hosting the annual Nordic-American Healthcare Conference.

Differentiator

Problem solved

Functional benefit

Brands

• DNB Carnegie Back Bay Healthcare Partnership: A strategic partnership providing integrated strategy and corporate and investment banking solutions for global and emerging life science and healthcare companies.
• The Life Science Report

Products and services

• Investment Banking Strategic and financial advisory services for life sciences companies including M&A advisory, licensing deals, and capital raising, delivered through Back Bay Life Science Advisory LLC, a wholly-owned FINRA/SIPC broker-dealer subsidiary.
• Strategic Advisory Data-driven strategy consulting to guide biotech, pharmaceutical, and medical technology companies through complex business, scientific, and financial challenges across commercial, R&D, and corporate development.
• Analytics Strategic insights and analytical services for life sciences companies and investors.
• DNB Carnegie Back Bay Healthcare Partnership Integrated strategy and corporate and investment banking solution providing strategic and financial support to global and emerging life science and healthcare companies through the partnership with DNB Markets, Inc.
• Healthcare Equity Analyst Reports Industry reports authored by Back Bay experts and DNB senior equity analysts covering healthcare sectors including oncology, biopharma, and drug development; distributed to subscribers via email.
• White Papers In-depth research reports on life sciences topics including US-China biotech dealmaking, RNA therapeutics, gene therapy, cell technology, obesity drugs, and radiopharmaceuticals.
• The Life Science Report (Podcast) Bi-monthly industry podcast featuring expert insights from advisors and investment bankers on life science development, with interviews featuring life sciences executives, scientific investigators, and biotech/medtech leaders; distributed on Apple Podcasts, Spotify, Libsyn, and Stitcher.
• Nordic-American Healthcare Conference (NAHC) Annual conference hosted by Back Bay and DNB Carnegie that connects US institutional healthcare investors with US and Nordic life science companies; the 10th edition was scheduled for March 25-26, 2026 in New York City.

Quantifiable outcome

• The DNB Carnegie Back Bay organized the 10th Annual Nordic-American Healthcare Conference (2026), uniting US and Nordic life science companies with US institutional healthcare investors.
• +2 more outcomes

Named customers15 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core and minor.

• DNB Markets / DNB CarnegiecoreStrategic or Co-development PartnerThe DNB Carnegie Back Bay Healthcare Partnership provides integrated strategy and corporate and investment banking solution for global and emerging life science and healthcare companies. DNB Markets, Inc. (a US registered broker-dealer and subsidiary of DNB Bank ASA) offers securities products and services in the US through the partnership, while Back Bay provides strategic advisory. The partnership hosts the Nordic-American Healthcare Conference and publishes joint healthcare equity analyst reports. In October 2024, DNB Bank ASA announced acquisition of Carnegie (DNB Bank acquired all shares of Carnegie Holding AB from Altor for approximately SEK 12 billion, expected to close H1 2025).
• DNB Carnegie / Back Bay Nordic Healthcare ConferencecoreStrategic or Co-development PartnerAnnual Nordic Healthcare Conference in Oslo (16th edition in 2025) is a collaboration between DNB, DNB Carnegie and Back Bay. Features listed and private healthcare companies presenting, one-on-one investor meetings, and the DNB//Back Bay Industry & Venture session focused on Nordic healthcare ecosystem development.
• Business Sweden, Business Finland, Innovation Norway, Innovation Centre DenmarkminorGTM or Marketing PartnerBack Bay participated in Nordic AMPlify 2021, co-funded by Nordic Innovation, to guide Nordic digital health and medtech companies on US market entrance. Partner organizations bring together Nordic healthtech companies for networking with Back Bay advisory support.
• Nordic InnovationminorGTM or Marketing PartnerNordic AMPlify 2021 project co-funded by Nordic Innovation as part of their Life Science and Health Tech program (2021-2024), with Back Bay providing US market expertise to participating Nordic companies.
• BioInnovation InstituteminorStrategic or Co-development PartnerThe BioInnovation Institute (Denmark) announced partnership with Back Bay Life Science Advisors to support emerging bioPharma companies with cross-border partnering and investment strategies.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• ZS Associates: ZS Associates is a large global consulting firm with a deep life sciences practice covering strategy, commercial, and analytics work for pharma and biotech clients. It overlaps with Back Bay's strategic advisory offering but as part of a much larger portfolio.
• Jefferies Healthcare Group: Jefferies runs a large healthcare investment banking franchise covering biopharma, medtech, and healthcare services globally. It competes for mid- and large-cap life sciences M&A mandates that Back Bay also targets, but as part of a much broader platform.
• Syneos Health Consulting: Syneos Health Consulting provides biopharma strategy, commercialization, and advisory services as part of its broader clinical and commercial solutions platform. It overlaps with Back Bay's strategic advisory and analytics services for life sciences.

Direct peers

• Torreya Partners: Torreya Partners is a global investment bank exclusively focused on life sciences, providing M&A advisory, equity capital markets, and strategic consulting. Like Back Bay, it operates as a sector-specialist advisor serving biotech and pharma clients.
• Locust Walk: Locust Walk is a boutique, life sciences-focused transaction advisory firm providing M&A, capital markets, and strategic advisory to biotech, pharma, and medtech clients. It competes head-to-head with Back Bay in the same client segment and engagement types.
• MTS Health Partners: MTS Health Partners is a boutique investment bank dedicated to healthcare M&A advisory, serving pharma, biotech, medtech, and healthcare services clients. It is a direct competitor for sell-side and buy-side mandates that Back Bay targets.
• Lumanity: Lumanity is a life sciences-focused consultancy offering strategic advisory, medical affairs, market access, and commercial services to biopharma and medtech clients. It overlaps with Back Bay's strategic advisory and analytics offerings for life sciences.
• Outcome Capital: Outcome Capital is a specialized life sciences advisory and investment banking firm providing M&A, licensing, and strategic advisory to emerging and mid-market biotech, medtech, and diagnostics companies — overlapping directly with Back Bay's core client base.
• Trinity Partners: Trinity Partners is a life sciences consulting firm providing strategy, market access, and transaction advisory to biopharma and medtech clients. Like Back Bay, it integrates strategic consulting with transaction support for life sciences companies.

Regional players

• Drakestar (Carnegie Investment Bank): Carnegie (now part of DNB Bank ASA following the 2024 acquisition) is a Nordic-domiciled investment bank with a strong life sciences franchise. It is a direct peer via the DNB Carnegie Back Bay partnership and competes for Nordic healthcare M&A and capital markets mandates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/backbayadvisors
• LinkedInlinkedin.com/company/back-bay-life-science-advisors
• Facebookfacebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.bblsa.com%2F

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Back Bay Life Science Advisors